BlackRock
CARM

BlackRock’s Carisma Therapeutics CARM Stock Holding History

BlackRock’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-336,789
Closed -$92.3K – 5550
2025
Q3 		$92.3K Hold
336,789
– – ﹤0.01% 4849
2025
Q2 		$132K Sell
336,789
-70,092
-17% -$18.8K ﹤0.01% 4774
2025
Q1 		$126K Sell
406,881
-1,266
-0.3% -$561 ﹤0.01% 4711
2024
Q4 		$171K Sell
408,147
-417
-0.1% -$344 ﹤0.01% 4655
2024
Q3 		$401K Sell
408,564
-301,476
-42% -$327K ﹤0.01% 4379
2024
Q2 		$1.08M Sell
710,040
-1,026,328
-59% -$1.53M ﹤0.01% 4159
2024
Q1 		$3.94M Sell
1,736,368
-131,061
-7% -$315K ﹤0.01% 3773
2023
Q4 		$5.47M Buy
1,867,429
+113,550
+6% +$338K ﹤0.01% 3655
2023
Q3 		$7.42M Sell
1,753,879
-29,359
-2% -$186K ﹤0.01% 3493
2023
Q2 		$15.6M Buy
1,783,238
+1,651,714
+1,256% +$8.99M ﹤0.01% 3183
2023
Q1 		$408K Sell
131,524
-149
-0.1% -$1.42K ﹤0.01% 4580
2022
Q4 		$1.61M Sell
131,673
-79,097
-38% -$831K ﹤0.01% 4228
2022
Q3 		$1.79M Buy
210,770
+6,337
+3% +$86.3K ﹤0.01% 4242
2022
Q2 		$3.31M Sell
204,433
-464,962
-69% -$5.32M ﹤0.01% 4004
2022
Q1 		$8.07M Sell
669,395
-5,035
-0.7% -$70.3K ﹤0.01% 3700
2021
Q4 		$11M Buy
674,430
+127,664
+23% +$2.57M ﹤0.01% 3618
2021
Q3 		$8.67M Buy
546,766
+13,875
+3% +$666K ﹤0.01% 3735
2021
Q2 		$49.2M Buy
532,891
+386,769
+265% +$24.7M ﹤0.01% 2716
2021
Q1 		$7.6M Buy
146,122
+50,879
+53% +$2.4M ﹤0.01% 3730
2020
Q4 		$2.57M Buy
95,243
+457
+0.5% +$11.6K ﹤0.01% 3960
2020
Q3 		$2.65M Hold
94,786
– – ﹤0.01% 3820
2020
Q2 		$1.36M Sell
94,786
-12,375
-12% -$167K ﹤0.01% 3952
2020
Q1 		$1.2M Sell
107,161
-183
-0.2% -$3K ﹤0.01% 3818
2019
Q4 		$2.23M Buy
107,344
+31,106
+41% +$715K ﹤0.01% 3753
2019
Q3 		$1.78M Buy
76,238
+3,556
+5% +$83.2K ﹤0.01% 3793
2019
Q2 		$2.18M Buy
72,682
+2,680
+4% +$80.2K ﹤0.01% 3751
2019
Q1 		$1.44M Buy
70,002
+99
+0.1% +$1.71K ﹤0.01% 3805
2018
Q4 		$1.99M Sell
69,903
-513
-0.7% -$16.4K ﹤0.01% 3667
2018
Q3 		$3.03M Buy
70,416
+3,471
+5% +$135K ﹤0.01% 3642
2018
Q2 		$2.61M Buy
66,945
+44,693
+201% +$1.97M ﹤0.01% 3647
2018
Q1 		$467K Sell
22,252
-21
-0.1% -$403 ﹤0.01% 4059
2017
Q4 		$361K Buy
22,273
+88
+0.4% +$1.64K ﹤0.01% 4102
2017
Q3 		$701K Sell
22,185
-85
-0.4% -$2.38K ﹤0.01% 3996
2017
Q2 		$699K Buy
22,270
+21
+0.1% +$700 ﹤0.01% 3936
2017
Q1 		$979K Buy
+22,249
New +$927K ﹤0.01% 3817
2014
Q2 		– Sell
-935
Closed -$304K – 3162
2014
Q1 		$304K Buy
+935
New +$280K ﹤0.01% 1438

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

BlackRock's CARM Position: Q4 2025 in Review

BlackRock sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 336,789 shares — an estimated $92.3K sold.

BlackRock first reported a position in CARM in Q1 2014 and held it in 36 quarters. The position peaked at $49.2M in Q2 2021. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • BlackRock reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • BlackRock sold 336,789 Carisma Therapeutics shares in Q4 2025, an estimated $92.3K.
  • BlackRock first reported a position in Carisma Therapeutics in Q1 2014 and held it in 36 quarters.
  • BlackRock's Carisma Therapeutics position peaked at $49.2M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on BlackRock's 13F filing for Q4 2025, filed 12 Feb 2026.